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INTRODUCTION AND OBJECTIVES 
Ipecac syrup is the emetic of choice for decontamination of the stomach in many drug 
overdoses and poison ingestions. Introduced into Europe from its native South America in the 17th 
century, ipecac (ipecacuanha, "Brazil Root") W8S used as a secret remedy for dysentery until 
France's King Louis XIV bought the secret and introduced the formula into the public domain.1 
Ipecac is derived from the dried root of Cephaelis ipecacuanha or C. acuminata, plants indigenous to 
Brazil and Central America, and cultivated 1n India and Malaysia.2 The active emetic principles in 
Ipecac have been identified as the alkaloids, emetine and cephaeline.3 Cephaeline produces greater 
nausea and vomiting than emetine, but emetine, which constitutes one third to one half of the total 
alkaloids in ipecac, is more toxic to the heart and other organs.3 Ipecac also contains the alkaloid 
psychotrlne which is believed to be less active and less toxic than the other two alkaloids.3 
Ipecac is used as an emetic iri the United States in the form of ipecac syrup USP. Ipecac syrup is 
inexpensive, readily available, easy to use, and relatively f8st acting.4"7 
The emetic action of ipecac fs thought to be the result of its centrally mediated emetic action 
accompanied by Its local Irritant action on the gastrointestinal tract. Evidence supporting the 
centrally mediated emetic action of ipecac syrup includes the work of Thumas which showed that 
local application of emetine in the area of the medulla produced vomiting in dogs,8 Eggleston and 
Hatcher later reported that emetine and cephaeline caused vomiting movements and symptoms of 
nausea in animals whose stomachs were completely removed.9 Evidence supporting a 
gastrointestinal irritant effect of ipecac includes the work of Weaver and Griffith.1 0 These 
investigators demonstrated that early vomiting (within 30 minutes) is due to the direct action of 
ipecac on the gastrointestinal tract and that late vomiting (vomiting occurlng 30 minutes or more 
2 
after administration of ipecac syrup) is a result of centrally induced vomiting. This evidence 
suggests that the mechanism of ipecac is twofold: a direct irritation of the gastrointestinal mucosa 
to initiate vomiting and stimulation of the chemoreceptor trigger zone to help propagate the emetic 
response. 
The oral administration of fluids, given immediately prior to or immediately after the ipecac 
ayrup, is thought to be of some clinical importance as an enhancement of emesis. Anecdotal 
information suggests that greater amounts of fluid taken by the patient concurrently with ipecac 
syrup produces more effective emesis. Wood and Bache in 1858 stated that the procedure "is 
facilitated by and rendered milder by giving fluid just after the syrup. About 200 ml of water or 
clear fluid should be given".11 In 1975 Arena advised: "The patient should also be given fluid 
( 1 to 2 glasses) several minutes after the ipecac is swallowed, since emesis may not occur if the 
stomach is empty".12 In 1980 King observed: "The oral administration of fluids, given just 
before or after the ipecac syrup, is of utmost importance In effectively inducing emesis."2 
Current widely accepted recommendations call for the administration of 2 - 4 ounces of clear fluids 
for infants 6 to 11 months old, 4 - 8 ounces of clear fluids for children 1 to 6 years old, and 8 - 1 6 
ounces of clear fluids for persons 7 years and older 2 However, these current recommendations 
are empiric aid have not been clinically tested for effectiveness. 
The objective of this study was to determine if a relationship exists between volume of fluids 
taken with ipecac syrup and volume of emesis produced. 
SUBJECTS 
Twenty volunteers were recruited to participate In the study. The volunteers were paid for 
their participation, and each volunteer signed a consent form (Appendix 1) approved by the 
University of Utah Institutional Review Board. 
3 
Volunteers were included in the stud/ if they were at least 18 years of age, currently healthy 
and free of chronic disease, and had a physical examination within 12 months prior to 
participation in the stud/. Volunteers were excluded from the stud/ if they were pregnant, taking 
any chronic medications other than birth control pills, or if they had a blood pressure or pulse 
which were not within normal limits prior to participation in either phase of the stud/. 
METHODS 
Each test session involved one subject, the investigator, and a trained observer-assistant. 
Arrangements were made with the University of Utah Hospitdl Emergency Department for use of 
their facilities. A physician was available at all times within the Emergency Department 
throughout each session. 
Vomiting was induced in each subject on two occasions separated by at least one week. The 
subjects were instructed to take nothing by mouth, solid or liquid, for at least eight hours prior to 
each session and remained seated throughout each session. For each session, the subject was 
induced to vomit by administering 30 ml of ipecac syrup and a measured amount of water. The 
vomitus from each subject was collected and measured by two independent observers, the 
investigator and a trained assistant. Both measurements were recorded. The average of the 
measurements was used as the volume of vomitus for analytical purposes. The time to onset of 
vomiting, the number of single and major vomiting episodes, and the duration of vomiting were 
also recorded for each subject (Appendix 2). For this stud/, a single vomiting episode was defined 
as an abdominal convulsion which resulted in the expulsion of material from the subject's mouth. 
A major vomiting episode was defined as several single vomiting episodes occurlng in rapid 
succession followed by 8 period of time when the subject reported that he/she no longer felt 
nauseous. Subjects were advised to take nothing by mouth for two hours following the last 
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vomiting episode. Esch subject was contacted by the principal investigator as a follow-up within 
24 hours of each testing episode to determine if any side effects had occurred. 
Subjects were divided into two groups by use of a random numbers table. Group 1 was given 
30 ml ipecac syrup with 240 ml (8 ounces) water at ambient temperature, and Group 2 was 
given 30 ml of ipecac syrup and 480 ml ( 1 6 ounces) of water at ambient temperature. The 
groups were then crossed-over, and the amount of water given with the ipecac syrup was switched 
between the two groups. 
In accordance with the objective of the study, the volume of vomitus was analyzed by a 
two-tailed Student's t-test with 8 level of significance 8t the p<0.05 level for paired data to 
determ ine if there is a statistically significant difference in the volume of vomitus produced with 
differing amounts of water. For academic interest, a stepwise multilinear regression analysis 
with a level of significance at the p<0,05 level W8S also performed on all the data gathered in this 
study. 
RESULTS 
Twenty subjects entered the study. Three subjects had to be dropped from the study and were 
not included in the statistical analysis (Table 1). One subject experienced vomiting and diarrhea 
lasting approximately eight hours and painful stomach cramps lasting approximately two days and 
declined to participate in the second phase of the study. Another subject was unable to swallow the 
ipecac syrup during the second phase of the stud/, and the third subject was subsequently found to 
suffer from chronic headaches, an exclusion criterion of the study (chronic disease). 
The average volume (±SEM) of emesis with 8 ounces of water and 1 ounce of ipecac syrup 
was 350 ± 15.8 ml. When 16 ounces of water and 1 ounce of ipecac syrup were given, the average 
volume of emesis was 548 ± 15.5 ml (Table 2, Figure 1). The difference in volume returned was 
significant (p<0.05) using a two-tailed Student's t-test for paired date. 
Other Data Collected 
Other data gathered for each subject during the course of this study Included time to onset of 
vomiting, number of single and major vomiting episodes, and duration of vomiting (Table 2). The 
average time to onset of vomiting (±SEM) with 8 ounces of water was 19 ± 2.4 minutes as 
compared to 15 ± 1.5 minutes with 16 ounces of water (Table 2, Figure 2). The average number 
of single vomiting episodes (±SEM) with 8 ounces of water was 22 ± 3.2 compared to 19 ± 1.8 
episodes with 16 ounces of water (Table 2, Figure 3). The average volume of emesis per single 
vomiting episode U S E M ) with 8 ounces of water was 22 ± 2.9 ml and 3? ± 4.6 ml with 16 ounces 
of water (Table 3). The average number of major vomiting episodes (±SEM) with 8 ounces of 
water was 5.0 ± 1.0 and 4.0 ± 0.46 with 16 ounces of water (Table 2 , Figure 4). Subjects' 
nausea would disappear for an average of 9.7 ± 1 . 1 minutes with 8 ounces of water or 10 ± 1.6 
minutes with 16 ounces of water before the next major vomiting episode (Table 3). The average 
volume of emesis per major vomiting episode was ! 10 ± 19.2 ml with 8 ounces of water and 149 
± 17.0 ml with 16 ounces of water (Table 3). The average duration of emesis (±SEM ) with 8 
ounces of water was 41 ± 7.0 minutes and 45 ± 5.0 minutes with 16 ounces of water 
(Table 2 , Figure 5). 
Using a stepwise multilinear regression analysis, the only variable which contributed 
significantly to the total volume of vomitus produced was the amount of fluids administered with 
the Ipecac syrup (p < 0.05). 
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significant (p<0.05) using a two-tailed Student's t-test for paired data. 
Other Data Collected 
Other data gathered for each subject during the course of this study included time to onset of 
vomiting, number of single and major vomiting episodes, and duration of vomiting (Table 2). The 
average time to onset of vomiting (±SEM) with 8 ounces of water was 19 ± 2.4 minutes as 
compared to 15 ± 1.5 minutes with 16 ounces of water (Table 2, Figure 2). The average number 
of single vomiting episodes (±SEM) with 8 ounces of water was 22 ± 3.2 compared to 19 ± 1,8 
episodes with 16 ounces of water (Table 2, Figure 3). The average volume of emesis per single 
vomiting episode (±SEM) with 8 ounces of water was 22 ± 2.9 ml and 3? ± 4.6 ml with 16 ounces 
of water (Table 3). The average number of major vomiting episodes (±SEM) with 8 ounces of 
water was 5.0 ± 1.0 and 4.0 ± 0.46 with 16 ounces of water (Table 2, Figure 4). Subjects' 
nausea would disappear for an average of 9,7 ± 1.1 minutes with 8 ounces of water or 10 ± 1,6 
minutes with 16 ounces of water before the next major vomiting episode (Table 3). The average 
volume of emesis per major vomiting episode was 110 ± 19.2 ml with 8 ounces of water and 149 
± 17.0 ml with 16 ounces of water (Table 3). The average duration of emesis (±SEM ) with 8 
ounces of water was 41 ± 7.0 minutes and 45 ± 5.0 minutes with 16 ounces of water 
(Table 2, Figure 5). 
Using a stepwise multilinear regression analysis, the only variable which contributed 
significantly to the total volume of vomitus produced was the amount of fluids administered with 
the Ipecac syrup (p < 0.05). 
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DISCUSSION 
This study W8s designed to answer a fundamental question concerning the relationship 
between the volume of fluids with ipecac syrup end the volume of the resulting emesis. The 
results of this study indicate that there is a relationship between administration of differing 
amounts of fluids with ipecac syrup and the volume of emesis. Sixteen ounces of water produced a 
volume of emesis that was significantly greater than the volume of emesis produced following 8 
ounces of water (p<0.05), 
Wh ile it appears intuitively logical that greater amounts of fluids given with ipecac syrup 
should result In greater volumes of vomitus, this may not necessarily be true. The volume of 
vomitus in cases of ipecac-induced emesis may be primarily due to the action of the emetic, rather 
than the volume of fluids administered, If this were the case, then administering the same volume 
of ipecac with differing amounts of fluids would yield the same volume of vomitus. 
A stepwise multilinear regression analysis was performed on all the data gathered tn the 
study. However, because of the small number of subjects in this study, differences between 
variables must be large in order for differences to be statistically significant. While no statistical 
significance was found relating volume of vomitus produced and time to onset of vomiting, this 
latter variable could influence the final volume of vomitus. Water may be absorbed during this 
time and be unavailable for emesis. Since most water absorption occurs in the colon, 
predominantly in the cecum,13 it would be necessary for a significant volume of water to leave j 
the stomach prior to the onset of vomiting in order to significantly effect the volume of induced i 
emesis, | 
A subjective observation made by all participants in the study was that the second phase of 
j 
the study "felt easier on the stomach". This observation occurred regardless of the amount of fluid 
1 
taken during the second phase. Because of the possible influence of the subjects' "experience" with 
vomiting during the second phase, Group 1 (subjects given 8 ounces of water first) was compared 
to Group 2 (subjects given 16 ounces of water first). The average number of single and major 
vomiting episodes and average duration of vomiting decreased during the second phase of the study 
for both groups (Table 4). These two factors were probably most influential in contributing to 
the subjective feelings of the subjects. The subjects* physiological and psychological disposition 
may have changed because of their experience with Ipecac. Emetine and cephaellne, the most 
abundant alkaloids in ipecac syrup, r e erratically absorbed following oral administration in 
human volunteers." The half-life of emetine following deep subcutaneous or intramuscular 
injection is 40-60 days.'"5.'16 Thehalf-lifeofcephaeline is not known. All subjects except 
three were separated from the two phases by seven days, Subject I was separated from the two 
phases by 26 days, subject 11 by 1 7 days, and subject 4 by 12 days, Erratic absorption of the 
ipecac alkaloids and the long half-life of emetine may have caused a physiological change which 
affected their reponse during the second phase of the study. Vomiting is an experience that most 
people find extremely unpleasant, Psychologically, the subjects may have felt less anxious about 
Ipecac's effects during the second phase of the study. These factors may have accounted for some of 
the differences between the groups in number of single vomiting episodes and duration of vomiting 
which were observed. This observation, however, is not cllncally relevant since patients in 
poisoning situations are given Ipecac on only one occasion. 
Also of interest is the comparison of subjects who received 8 ounces of water for the first 
phase and subjects who received 8 ounces of water for the second phase (Table 5), A similar 
comparison was made between subjects receiving 16 ounces of water for the first phase and 
subjects who received 16 ounces of water for the second phase (Table 6). The average values for 
time to onset of vomiting, number of single and major vomiting episodes, duration of vomiting, and 
volume of vomitus between the groups for the 16 ounce test are reasonably similar. However, the 
average values for these same categories between the groups for the 8 ounce test r e quite 
different. Because the subjects were randomly assigned to the order in which the 8 ounces and 16 
ounces of water were given, this difference is unlikely an artifact of the data gathering process but 
may be the result of the coveriance of the data. 
Toxicity from ipecac alkaloids may Involve the cardiovascular or neuromuscular systems, 
the gastrointestinal tract, as well as prolonged vomiting, aspiration of vomitus, and bloody 
diarrhea. 1 7 - 2 2 However, clinically significant toxicity from the use of this emetic drug is 
unusual and has most often occurred as a result of intentional ipecac overdose, inappropriate 
administration at home, or Inadvertent administration of fluid extract of ipecac which 1s 14 times 
more potent than ipecac syrup. Side effects from the administration of ipecac syrup were minimal 
in this study. All subjects felt drowsy after completing each separate phase of the study. Six of 
the 1 7 subjects ( 3 5 1 ) reported having mild to moderate diarrhea. The diarrhea usually occurred 
within two hours after taking the Ipecac syrup and usually resolved within six hours. No other 
side effects were noted. No subject reported vomiting after leaving the health care facility. 
CONCLUSION 
This study establishes a relationship between volume of fluids taken with ipecac syrup and 
the volume of the resulting emesis. When a 16 ounce volume of water was administered after the 
ipecac syrup, a statistically greater volume of emesis was returned than when an 8 ounce volume 
of water was administered. Although not statistically significant in this study, there was a trend 
toward a shorter time to onset of vomiting, fewer number of single vomiting episodes, and more 
volume per vomiting episode when 16 ounces of water was administered. Such a trend was not 
seen when compering the duration of vomiting between the two different volumes of fluid 
administered Therefore, a more efficient emetic reponse was produced when 16 ounces of water 
was administered. 
The significance of this study as it relates to the emergency treatment of ingested poisons 
rests on the assumption that a greater volume of emesis returns a greater amount of the poison( s) 
ingested by the patient. If this assumption is valid, then these data suggest that larger amounts of 
Ingested poisons can be removed from a patient by administration of larger volumes of fluid with 
ipecac syrup. Future studies might administer a non-toxic dose of a drug to test subjects. Some 
time later these subjects would be administered ipecac syrup along with differing amounts of 
fluids. After the induced emesis, blood levels of the previously administered drug would be 
measured. Such a stud/ would help determine If a relationship does exist between the volume of 
induced emesis and the effective removal of ingested poisons. 
The results from this study suggest that a more efficient emesis is produced when 16 ounces 
of water is given with 1 ounce of ipecac syrup, and I would, therefore, recommend that larger 
volumes of fluid be administered when optimal emesis is needed. 
TABLES 
1 1 
Table 1. Subject characteristics 
Subject Age Sex Weight 
(yrs) (lbs) 
1 30 F 140 
2 31 F 120 
3 22 M 212 
4 18 M 165 
5 24 F 176 
6 18 F 175 
7 26 M 172 
8 20 M 175 
9 35 F 125 
10 23 M 172 
11 19 F 105 
12 20 F 138 
13 45 F 125 
14 20 F 115 
15 21 F 120 
16 24 F 130 
17 25 M 165 
Mean ± SEN 25 ± 1.7 149 ± 7 . 1 6 
12 
Table 2. Time to onset, number of single and major vomiting episodes, duration, and 
volume of ipecac-induced emesis with differing amounts of water 
Subject 6roup Time to onset No. of single No. of major Duration Volume 
* (min) episodes episodes (min) (ml) 
8 o z . 1 6 o z . 8 o z . 1 6 o z . 8 o z . 1 6 o z . 8 o z , 1 6 o z , 8 o z . 1 6 o z . 
1 1 22 20 3 7 28 06 04 94 26 445 510 
2 2 23 06 16 20 03 03 22 44 315 550 
3 2 21 17 12 1 7 02 03 14 50 298 540 
4 1 12 14 36 27 10 0 7 5B 7 2 435 485 
5 1 10 0 7 28 18 10 06 45 24 390 630 
6 1 11 18 18 20 08 06 51 58 358 545 
7 1 13 10 29 24 0 7 05 66 66 345 5 7 0 
8 2 19 11 1 7 29 03 05 38 61 360 545 
9 1 08 08 29 23 04 04 61 66 360 690 
10 1 13 23 12 10 03 02 11 11 360 600 
11 2 11 08 15 10 04 06 36 33 337 653 
12 2 46 29 07 08 Of 02 02 63 360 540 
13 2 20 11 13 21 03 05 4 7 69 400 480 
14 2 24 12 04 0 7 01 02 01 16 180 5 1 0 
15 1 15 1 7 56 09 1 7 03 9 7 2 7 270 450 
16 2 36 19 11 19 02 02 12 25 305 5 1 0 
1 7 2 22 16 25 29 04 08 41 59 423 5 1 0 
Mean 19 15 22 19 5.0 4,0 41 45 350 548 
SEM 2.4 1.5 3,2 1 .8 1.0 0,46 7 , 0 5.0 15.8 15.5 
Table 3. Time between vomiting episodes, ml/single episode, and ml/major episode of 
ipecac-induced emesis with differing amounts of water 
ml/ single episode 
ml/major episode 
Time between vomiting episodes 
(min) 
802. 
(Mean ± SEM) 
22 ± 2.9 
110 ± 19.2 
9.7 ± 1.1 
16oz. 
(Mean ± SEM) 
3 7 ± 4.6 
1 4 9 * 17.0 
10 ±1.6 
14 
Table 4, Comparison between the first and second phases In 0roup 1 and the first and second 
phases in Group 2 
Group 1 Group 2 
1st phase 2nd phase 1st phase 2nd phase 
time to onset, min 13 ± 1 . 5 15 ± 2 . 1 14 ± 2.3 25 ± 3.4 
(mean ± SEM) 
* of single episodes 31 ± 4 . 7 20 ± 2 . 5 18 ± 2 . 7 13 ±2.0 
(mean ± SEM) 
* of major episodes 8.1 ± 1 . 6 4.6 ± . 6 0 4.0 ± . 7 1 2.6 ±.38 
(mean ± SEM) 
duration, min 60 ± 9 . 7 44 ± 8.5 47 ±6.2 24 ±5.8 
(mean ± SEM) 
volume, ml 370 ± 1 9 . 2 560 ±28.0 538 ± 1 6 . 3 331 ±23.5 
(mean ± SEM) 
Table 5. Comparison between subjects given 8 ounces of water first and subjects given 8 
ounces of water second 
8 oz 1st 8 02 2nd 
no. of subjects 
sex 3li 3li 
5F 6F 
weight, lbs 156 ±8.05 143± 11.5 
(mean ± SEM) 
age.yrs 24 ±2.1 25 ±2.8 
(mean ± SEM) 
time to onset, min 13 ± 1 . 5 25 ±3.4 
(mean ± SEM) 
* of single episodes 31 ± 4.7 13 ± 2.0 
(mean ± SEM) 
* of major episodes 8.1 ± 1 . 6 2.6 ±.38 
(mean ± SEM) 
duration, min 60 ± 9.7 24 ± 5.8 
(mean ± SEM) 
volume, ml 3 7 0 ± 19.2 331 ± 23.5 
(mean ± SEM) 
Table 6, Comparison between subjects given 16 ounces of water first and subjects given 
16 ounces of water second 
16 oz 1st 16 oz 2nd 
no, of subjects 
sex 3f1 3M 
6F SF 
weight, lbs 143 ± 1 1 . 5 156 ±8,05 
(mean ± SEM) 
age.yrs 25 ± 2 . 8 24 ± 2 . 1 
(mean ± SEM) 
time to onset, min 14 ± 2 . 3 15 ± 2 . 1 
(mean ± SEM) 
* of single episodes 18 ± 2.7 20 ± 2.5 
(mean ± SEM) 
* of major episodes 4.0 ± .11 4.6 ± .60 
(meant SEM) 
duration, min 47 ± 6,2 44 ± 8,5 
(mean ± SEM) 
volume, ml 538 ± 16.3 560 ± 28.0 
(mean ± SEM) 
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PARTICIPANT CONSENT FORM 
You are Invited to participate in a pharmaceutical research project Involving ipecac syrup, a 
stomach irritant which induces vomiting. The purpose of this research is to determine if a 
relationship exists between volume of fluids taken with ipecac syrup and volume vomited. 
As a participant, you will be Induced to vomit on two separate occasions. For each occasion, you 
will have taken nothing by mouth, solid or liquid, in the past eight hours. You will be given 
differing amounts of water to drink with the Ipecac syrup. The amount you vomit will be collected 
for measurement. 
The duration of each occasion is dependent on the length of time the ipecac syrup requires to induce 
vomiting (usually 20 minutes) and the amount of time spent vomiting (may continue for up to 2 
tours). 
Harmful side effects from the use of ipecac syrup may involve the heart, nerve and muscle 
systems, the stomach and intestinal tract, prolonged vomiting, and aspiration of vomitus. 
However, these effects are extremely rare when ipecac syrup is properly administered. I pecac 
syrup has maintained a remarkable record of safety. 
In the event you sustain physical injury resulting from the research project in which you are 
participating, the University of Utah will provide you, without charge, emergency and temporary 
medical treatment not otherwise covered try insurance. Furthermore, if your injuries are caused 
by negligent acts or (missions of University employees acting in the course and scope of their 
employment, the University may be liable, subject to limitations prescribed by law, for additional 
medical costs and other damages you sustain. If you believe that you have suffered a physical 
injury as a result of participation in this research program, please contact the Office of Research 
Administration, phone number 581 -6903. 
For completing both phases of the study you will receive $ 100.00. The compensation is offered 
for your inconvenience. Your participation is voluntary, and you may withdraw from the study at 
any time, Approximately 20 participants will be Involved in this study. 
Confidentiality of records which identify you by name will be maintained, although the Food and 
Drug Administration may inspect the records. 
Please contact Ellen Jarvls for answers to any questions you may have about this research. The 
telephone number is 583-9256. 
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PARTICIPANT CONSENT FORM 
By signing below you affirm that you have read and fully understand your participation in, and the 
nature of, this research. 
Participant's Name (please print) Date 
Signature of participant 
APPENDIX 2 
Participant * — 
Age — 
Consent Form — 
NPO 8 hours? — 
Date 





Mean Volume (ml) 
Follow-up 
(Date & Time) 
Date taken by: 
PARTICIPANT DATA FORM 
Telephone * -
Sex (M or F) - - Weight — __ 
Physical Exam 
8 oz. 16 oz. 
/ 
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